Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Food safety diagnostics might feel far from Wall Street, yet Neogen鈥檚 supply-chain complexity shows up in hundreds of pages of disclosures. Tracking which genomic test kit drives revenue, or when management sells shares, is difficult. That鈥檚 why investors hunting for 鈥淣eogen insider trading Form 4 transactions鈥� or the latest 鈥淣eogen quarterly earnings report 10-Q filing鈥� often lose hours scrolling through EDGAR.
Stock Titan fixes this. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment it is released, pushes 鈥淣eogen Form 4 insider transactions real-time鈥� to your dashboard, and offers 鈥淣eogen SEC filings explained simply鈥� with crisp language and data visualizations. Within seconds you鈥檒l see a 鈥淣eogen earnings report filing analysis,鈥� flagging segment sales for food safety, animal safety and genomics, plus cash flow shifts tied to acquisitions. Interactive links jump you straight to risk factors, while sidebars answer 鈥渦nderstanding Neogen SEC documents with AI鈥� without legalese.
Want specifics? The 鈥淣eogen annual report 10-K simplified鈥� highlights R&D spend on LAMP molecular assays and global compliance costs. The 鈥淣eogen proxy statement executive compensation鈥� module benchmarks pay packages against peer diagnostics firms. Alerts on 鈥淣eogen executive stock transactions Form 4鈥� reveal buying patterns before material announcements, and our dashboard keeps the 鈥淣eogen 8-K material events explained鈥� in plain sight when recalls or mergers hit. Whether you compare quarter-over-quarter allergen test kit sales, monitor insider sentiment, or review governance votes, Stock Titan delivers the intelligence you need, updated in real time and ready for decision making.
Neogen Corp. (NEOG) filed its FY-2025 Form 10-K covering the year ended 31 May 2025. The Lansing-based food & animal safety company reports a two-segment structure: Food Safety contributed 71.3 % of FY-25 revenue (vs. 70.9 % FY-24) while Animal Safety supplied 28.7 %. International sales grew to 50.2 % of total. The group employs 2,974 people across 28 countries.
Strategic actions include the April 2025 agreement to divest the global Cleaners & Disinfectants unit and ongoing integration of the 3 M Food Safety Division acquired in Sept 2022 (Reverse Morris Trust). Management still targets cost and revenue synergies but acknowledges impairment charges on the Food Safety reporting unit recorded in Q2 and Q4 FY-25.
Key risk disclosures: (1) Material weaknesses in internal control over financial reporting, mainly ineffective review controls for goodwill valuation; (2) continued challenges merging 3 M鈥檚 manufacturing footprint; (3) exposure to tariffs, supply-chain disruption, cybersecurity threats and geopolitical instability; (4) dependence on third-party logistics and single-source suppliers. R&D spend remains at 2-3 % of revenue; no customer represents 鈮�10 % of sales. Common stock outstanding: 217.2 m shares (30 Jun 2025); public float valued at $2.72 bn (30 Nov 2024).
Norges Bank, manager of Norway鈥檚 sovereign wealth fund, filed Amendment No. 3 to Schedule 13G on Neogen Corp (NEOG) as of 30 Jun 2025. The bank now reports beneficial ownership of 9,076,830 common shares, representing 4.2 % of outstanding stock. All shares are held with sole voting and dispositive power; there is no shared power with other parties.
The filing indicates that Norges Bank鈥檚 stake has fallen below the 5 % threshold, activating the 鈥淥wnership of 5 Percent or Less鈥� disclosure in Item 5. The shares are held on behalf of the Government of Norway and were acquired in the ordinary course of business, with no intent to influence control of the issuer. Aya Sobhy signed the certification on 24 Jul 2025.
Neogen Corp. (NEOG) filed an 8-K disclosing a leadership change. The Board appointed Mikhael Nassif, age 49, as President & CEO effective 11 Aug 2025. Nassif joins from Siemens Healthineers, where he led the global Point-of-Care Diagnostics unit, and previously held senior posts at Baxter, AB InBev, and Johnson & Johnson. The filing states there are no related-party transactions or pre-existing arrangements tied to the appointment.
Compensation package: (1) Base salary $800k, subject to review; (2) Annual bonus target 100% of salary, payout range 0鈥�250%, eligible for the full FY26 cycle; (3) Annual long-term equity grant targeted at $4.5 m; (4) One-time sign-on equity grant of $2 m (50% options, 50% RSUs, 4-year ratable vesting); (5) One-time cash award $500k payable by 5 Sep 2025, repayable if employment ends within one year; (6) Relocation support with full claw-back in year 1 and 50% in year 2; (7) Standard executive severance and benefit programs. A copy of the offer letter is filed as Exhibit 10.1. The company also issued a press release announcing the appointment.
FAQ
What is the current stock price of Neogen (NEOG)?
What is the market cap of Neogen (NEOG)?
